Future Oncology

Papers
(The H4-Index of Future Oncology is 30. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-11-01 to 2024-11-01.)
ArticleCitations
First-Line Pembrolizumab/Placebo Plus Trastuzumab and Chemotherapy in Her2-Positive Advanced Gastric Cancer: KEYNOTE-811115
Neoadjuvant Osimertinib With/Without Chemotherapy Versus Chemotherapy Alone for EGFR -Mutated Resectable Non-Small-Cell Lung Cancer: NeoADAURA87
The Abscopal Effect of Radiation Therapy74
Immune-Based Combinations for Advanced Hepatocellular Carcinoma: Shaping the Direction of First-Line Therapy73
An Insight Into the Cancer Stem Cell Survival Pathways Involved in Chemoresistance in Triple-Negative Breast Cancer72
KEYNOTE-975 Study Design: a Phase III Study of Definitive Chemoradiotherapy Plus Pembrolizumab in Patients with Esophageal Carcinoma72
MAHOGANY: Margetuximab Combination in HER2+ Unresectable/metastatic Gastric/gastroesophageal Junction Adenocarcinoma70
MATTERHORN: phase III study of durvalumab plus FLOT chemotherapy in resectable gastric/gastroesophageal junction cancer56
MARIPOSA: phase 3 study of first-line amivantamab + lazertinib versus osimertinib in EGFR-mutant non-small-cell lung cancer53
Systemic Therapy of Advanced Hepatocellular Carcinoma52
Immune-Related Adverse Events with PD-1 Versus PD-L1 Inhibitors: A Meta-Analysis of 8730 Patients from Clinical Trials49
The LEAP Program: Lenvatinib Plus Pembrolizumab for the Treatment of Advanced Solid Tumors47
Benefits and Limitations of Real-World Evidence: Lessons from EGFR Mutation-Positive Non-Small-Cell Lung Cancer45
CDK4/6 Inhibitors in HR+/HER2- Advanced/metastatic Breast Cancer: A Systematic Literature Review of Real-World Evidence Studies44
Organ Tropism in Solid Tumor Metastasis: An Updated Review43
RATIONALE 311: tislelizumab plus concurrent chemoradiotherapy for localized esophageal squamous cell carcinoma41
Atezolizumab and Bevacizumab for Hepatocellular Carcinoma: Mechanism, Pharmacokinetics and Future Treatment Strategies39
Cancer and COVID-19: Analysis of Patient Outcomes37
Perceptions of the COVID-19 vaccine Among Patients With Cancer: A Single-Institution Survey36
KEYNOTE-859: a Phase III Study of Pembrolizumab Plus Chemotherapy in Gastric/Gastroesophageal Junction Adenocarcinoma36
Oncolytic viruses: challenges and considerations in an evolving clinical landscape35
Dostarlimab in the Treatment of Recurrent or Primary Advanced Endometrial Cancer34
Talazoparib plus enzalutamide in metastatic castration-resistant prostate cancer: TALAPRO-2 phase III study design32
Multicenter phase II trial of trastuzumab deruxtecan for HER2-positive unresectable or recurrent biliary tract cancer: HERB trial32
Precision Oncology: a Clinical and Patient Perspective31
MOMENTUM: Momelotinib Vs Danazol in Patients with Myelofibrosis Previously Treated with JAKi Who Are Symptomatic and Anemic31
GALNT14 Regulates Ferroptosis and Apoptosis of Ovarian Cancer Through the EGFR/mTOR Pathway31
Phase III Study of Selpercatinib Versus Chemotherapy ± pembrolizumab in Untreated RET Positive Non-Small-Cell Lung Cancer31
INSIGHT 2: a Phase II Study of Tepotinib Plus Osimertinib in MET -Amplified NSCLC and First-Line Osimertinib Resistance31
Survival and Complications After Neoadjuvant Chemotherapy or Chemoradiotherapy for Esophageal Cancer: A Meta-Analysis30
A Ferroptosis-Related Gene Signature Predicts Overall Survival in Patients with Lung Adenocarcinoma30
Immunogenicity and Safety of the Coronavac Vaccine in Patients with Cancer Receiving Active Systemic Therapy30
0.40674614906311